Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
FDA: For intravenous administration as a source of water, calories, and electrolytes in patients requiring parenteral fluid therapy.,Off-label: Treatment of hypovolemia, hyponatremia, and hyperkalemia.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose: Not applicable as it is rapidly metabolized. Sodium: Not applicable (homeostatically regulated). Chloride: Not applicable (follows sodium). Clinical context: Half-life concepts do not apply; steady state for electrolytes depends on infusion rate and renal function.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of unchanged dextrose. Sodium and chloride are primarily excreted renally with >90% of filtered load reabsorbed; excess is excreted in urine. Biliary/fecal: Negligible.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: Not bound. Sodium: Not bound. Chloride: Not bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: 0.2–0.3 L/kg (total body water). Sodium and chloride: 0.2–0.3 L/kg (extracellular fluid). Clinical meaning: Distributes predominantly in extracellular fluid; expands plasma and interstitial volume.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
IV: 100% (by definition).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR 30-60 m L/min: no specific adjustment; monitor volume status and serum electrolytes. For GFR <30 m L/min: use with caution; may require volume restriction and monitoring for hyperchloremic metabolic acidosis.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific Child-Pugh based adjustments; use with caution in patients with cirrhosis due to risk of fluid overload and hyponatremia.
No dosage adjustment required for hepatic impairment.
Weight-based infusion: 0.9% sodium chloride equivalent at 4-8 m L/kg/hour; adjust based on serum sodium and glucose levels. For maintenance: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for additional weight.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use with caution; lower initial infusion rates (e.g., 50-100 m L/hour) due to increased risk of fluid overload and electrolyte disturbances. Monitor serum sodium and glucose frequently.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or impaired glucose tolerance.,Risk of fluid overload, especially in patients with renal impairment or cardiac disease.,Risk of dilutional hyponatremia, particularly in patients with increased ADH production.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to any component.,Clinically significant hyperglycemia or hypernatremia.,Use in patients with intracranial or intraspinal hemorrhage, or conditions causing severe dehydration with anuria.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No direct food interactions. However, sodium content (0.225% = 34.5 m Eq/L) should be considered in patients on sodium-restricted diets. Dextrose may affect glucose tolerance; monitor intake in diabetic patients.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Excreted in breast milk; M/P ratio not established. Dextrose and sodium chloride are normal constituents of milk; use during lactation is considered safe.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustment required; pharmacokinetics of dextrose and sodium chloride are not significantly altered in pregnancy. Use caution in patients with gestational diabetes or preeclampsia.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This hypotonic solution (225 m Osm/L) is suitable for maintenance hydration in normonatremic patients. Monitor serum sodium to avoid hyponatremia, especially in children, elderly, or those with impaired renal function. Do not use for resuscitation or in patients with hyponatremia. Contains 5% dextrose providing 170 kcal/L; consider in catabolic states.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution provides water, sugar, and salt to maintain hydration and energy.,Tell your doctor if you have swelling (edema), heart failure, or kidney problems.,Inform your doctor if you are on a low-sodium diet.,You may experience weight gain or swelling if too much fluid is given.,Do not self-adjust the infusion rate.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is: Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.